

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462

## Briumvi (Ublituximab)

PHYSICIAN I	PATIENT INFORMATION								
* Physician's Name:			*Due to privacy regulations we will not be able to respond via fax						
Specialty:	* DEA, NPI or	TIN:	with the outcome of our review unless all asterisked (*) items on this form are completed.*						
Office Contact Person:			* Patient Name:						
Office Phone:			* Cigna ID:			* Date of Birth:			
Office Fax:			* Patient Street Address:						
Office Street Address:			City		State Zip				
City	State	Zip	Patient Phone:	ə:					
Urgency: Standard Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)									
Medication requested:       Image: Other (please specify):         Briumvi 150 mg/6 mL (25 mg/mL) vial       Image: Other (please specify):									
Directions for Use: Nose: Quantity: Duration of therapy: ICD10:									
Is this a new start or continuation of therapy with the requested medication? If patient has been taking samples, please pick "new start." ☐ new start of therapy ☐ continuation of therapy									
(if continuation of therapy) Was there a previous prior authorization for this drug given by Cigna?									
(if continuation of thera ☐ No	a beneficial respon	beneficial response to this medication?							
(if no) Please provide support for continued use.									
Where will this medication Accredo Specialty Pharmacy Prescriber's office stock (billi Other (please specify):		🗌 Home He	☐ Retail pharmacy ☐ Home Health / Home Infusion vendor * <i>Cigna's nationally preferred specialty pharmacy</i>						
**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557									
Facility and/or doctor disperent Facility Name: Address (City, State, Zip Code):	nedication: Tax ID#:								
NOTE: Per some Cigna plans, infusion of medication MUST occur in the lowest cost, medically appropriate setting									
Is this infusion occurring in a facility affiliated with hospital outpatient setting?									
If yes- Is this patient a candidate for re-direction to an alternate setting (such as AIS, MDO, home) with assistance of a Specialty Care Option Case Manager?  Yes No (provide medical necessity rationale):									
Is your patient a candidate for home infusion? Does the physician have an in-office infusion site?				Yes 🗌 No 🗌 Yes 🗌 No 🗌					

Is the requested medication for a chronic or long-term condition for which the prescription medication may be nece the patient?	ssary for the life of ☐ Yes ☐ No					
What is your patient's Diagnosis: Multiple Sclerosis (MS) other (please specify):						
<ul> <li>(if MS) Please indicate which type of Multiple Sclerosis (MS) applies to your patient.</li> <li>☐ Active Secondary Progressive Multiple Sclerosis (SPMS) (for example, SPMS with a documented relapse)</li> <li>☐ Clinically Isolated Syndrome (CIS)</li> <li>☐ Relapsing-Remitting Multiple Sclerosis (RRMS)</li> <li>☐ Non-relapsing forms of multiple sclerosis (for example, primary progressive multiple sclerosis)</li> <li>☐ none of the above</li> </ul>						
(if none of the above) What is the patient's diagnosis or reason for treatment?						
Clinical Information:						
Has the patient been treated with ANY MS disease-modifying therapies?	🗌 Yes 🗌 No					
Has your patient tried any of the following? (check all that apply) dimethyl fumarate (generic for Tecfidera) fingolimod (generic for Gilenya)						
For the alternatives tried, please include drug name and strength, date(s) taken and for how long, and what the do were of taking each drug. For the alternatives NOT tried, please provide details why your patient can't try that drug						
Per the information provided above for dimethyl fumarate (generic for Tecfidera), which of the following is true for y to the covered alternative?  The patient tried the alternative, but it didn't work. The patient tried the alternative, but they did not tolerate it. The patient cannot try the alternative because of a contraindication to this drug. Other	our patient in regard					
Per the information provided above for fingolimod (generic for Gilenya), which of the following is true for your patient in regard to the covered alternative?  The patient tried the alternative, but it didn't work. The patient tried the alternative, but they did not tolerate it. The patient cannot try the alternative because of a contraindication to this drug. Other						
Besides the drug being requested, other disease-modifying agents used for multiple sclerosis include: Aubagio, Avonex, Bafiertam, Betaseron/Extavia, Briumvi, Copaxone/Glatopa, dimethyl fumarate, fingolimod, glatiramer, Gilenya, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Plegridy, Ponvory, Rebif, Tascenso ODT, Tysabri, Tecfidera, teriflunomide, Vumerity, and Zeposia. Which of the following best describes your patient's situation? The patient is NOT taking any other drug at this time, nor will they in the future. The requested drug is the only drug the patient is/will be using. The patient is currently on another drug, but this drug will be stopped and the requested drug will be started. The patient is currently on another drug, and the requested drug will be added. The patient may continue to take both drugs together. The patient is currently on BOTH the requested drug AND another drug.						
☐ other (if other/more than the requested drug) Please provide the rationale for concurrent use.						
Additional Information: (Please provide any additional pertinent clinical information, including: if the patient is requested drug (with dates of use) and how they have been receiving it (for example: samples, out of pocket).	currently on the					

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

## Prescriber Signature:

Date:

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005 v081524